Boehringer Ingelheim Launches University of Medicine Excellence
Inaugural ’Accelerate’ program designed and delivered by Harvard Medical School Executive Education with the goal of accelerating clinical development and medical affairs
- The University of Medicine Excellence will help Boehringer Ingelheim to accelerate progress in turning patient-focused innovation into life-changing treatments
- Harvard Medical School will deliver the first customized program, ‘Accelerate’, to create the next generation of leading experts in clinical development and medical affairs
- Investment of 3.4 million USD until end of next year
Ingelheim, October 12, 2021 – Boehringer Ingelheim today announced the launch of its University of Medicine Excellence (UME). In an unequivocal demonstration of commitment to people development and investment in a continuous learning culture, the company has officially launched UME and appointed the world-renowned Harvard Medical School (HMS) to deliver its inaugural program, ‘Accelerate’. Until end of next year, Boehringer Ingelheim will invest 3.4 million USD into the program.
UME supports the company in attracting and developing the next generation of leading experts in clinical development and medical affairs. It will be a place where learning focuses on giving people the skills to achieve Boehringer Ingelheim’s transformation goals, aimed at bringing innovative treatments to patients faster than ever before.
“Working with HMS will help us equip our internal medical professionals with the perspectives, tools and insights needed to create more value amid this complex and changing health care landscape”, says Guido Scholze, Head of UME.
Boehringer Ingelheim’s Corporate Senior Vice President of Medicine and Chief Medical Officer, Dr Mehdi Shahidi is equally confident that UME has the ability to boost the company’s transformation goals. “We believe investing in our people is fundamental as we strive for excellence and to achieve our ambitions of successfully developing new medicines”, he said. “Working together with HMS, UME’s inaugural program will help us to accelerate progress in areas of unmet medical need and deliver breakthrough therapies to patients around the world.“
“The Accelerate program has been designed to develop agile leaders who are highly sophisticated in digital and data strategies, and are truly patient-centric in their mindsets – all in service of meaningfully improving the lives of patients,” said Dr. Stanley Y. Shaw, Associate Dean for Executive Education at HMS.
The program combines state-of-the-art clinical development, cutting edge medical affairs and advanced business management training in a live setting with interconnected peer development. Approximately 1000 learners will embark on the four-month program over the next year and a half. Working together to develop the curriculum for Accelerate has brought to light a shared passion for excellence and positive patient outcomes.
Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
- Related Links